BriaCell Therapeutics(BCTXZ)
WEST VANCOUVER, British Columbia, CanadaBiotechnology
Focus: BriaCell Therapeutics is an oncology-focused immunotherapy biotech developing personalized cell-based cancer vaccines, with a lead program in breast cancer currently in Phase 3. The company is publicly traded on the TSX but operates at pre-revenue stage with minimal cash reserves.
Profile data last refreshed 16h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About BriaCell Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow BriaCell Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from BriaCell Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
SV-BR-1-GM
BreastcancerClinical Trials (1)
NCT03066947SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer
Phase 1/2Help build intelligence for BriaCell Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.